| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/15/2007 | US20070036756 Method for treating ischemic diseases |
| 02/15/2007 | US20070036755 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036754 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036753 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036752 IL-2 fusion proteins with modulated selectivity |
| 02/15/2007 | US20070036751 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| 02/15/2007 | US20070036750 MCP1 fusions |
| 02/15/2007 | US20070036749 Method of determining cytokine dosage for myelosuppressive state |
| 02/15/2007 | US20070036748 Combination therapies for cancer |
| 02/15/2007 | US20070036747 Pharmaceutical combination useful for stem cell mobilization |
| 02/15/2007 | US20070036744 Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| 02/15/2007 | US20070036742 Methods and compositions for modulating hair growth or regrowth |
| 02/15/2007 | US20070036719 antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis; prostate specific membrane antigen (PSMA) |
| 02/15/2007 | DE202006017823U1 Dietic food with increased effect of free radical binder, useful, e.g. for the treatment of allergic condition disease, comprises a protein and a sugar |
| 02/15/2007 | DE102005037791A1 Verwendung von spezifischen Trifluormethylketonen zur Vorbeugung und Behandlung einer Pankreatitis Use of specific trifluoromethyl ketones for the prevention and treatment of pancreatitis |
| 02/15/2007 | CA2659961A1 Targeted protein kinase c inhibitors and uses thereof |
| 02/15/2007 | CA2659958A1 Peptides targeted to protein kinase c isoforms and uses thereof |
| 02/15/2007 | CA2658678A1 Composition and method for prevention and treatment of type i diabetes |
| 02/15/2007 | CA2619443A1 Glypican-3 (gpc3)-derived tumor rejection antigenic peptides useful for hla-a2-positive patients and pharmaceutical comprising the same |
| 02/15/2007 | CA2618765A1 Methods for treating b-cell malignancies using taci-ig fusion molecule |
| 02/15/2007 | CA2618763A1 Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
| 02/15/2007 | CA2618750A1 Inhibitors of cancer cell, t-cell and keratinocyte proliferation |
| 02/15/2007 | CA2618666A1 A kit of lyophilized thrombin and lyophilized fibrinogen used to compound fibrin membrane, and its application |
| 02/15/2007 | CA2618600A1 Reducing post-operative adhesion formation with intraperitoneal glutamine |
| 02/15/2007 | CA2618396A1 Tissue protective peptides and uses thereof |
| 02/15/2007 | CA2618256A1 Modulation of cell fates and activities by phthalazinediones |
| 02/15/2007 | CA2618093A1 Composition and method for use in cartilage affecting conditions |
| 02/15/2007 | CA2618047A1 A novel peptide involved in energy homeostasis |
| 02/15/2007 | CA2618028A1 Polypeptides useful for appetite suppression |
| 02/15/2007 | CA2617960A1 A novel nucleic acid encoding a novel protein of candida albicans and uses thereof |
| 02/15/2007 | CA2617940A1 Materials useful for support and/or replacement of tissue and the use thereof for making prostheses |
| 02/15/2007 | CA2616831A1 Treatment of wounds using il-17b |
| 02/15/2007 | CA2616551A1 Chimeric therapeutic agents |
| 02/15/2007 | CA2616069A1 Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin |
| 02/15/2007 | CA2616041A1 Process for controlling protein to salt ratio in animal muscle protein composition and protein composition |
| 02/15/2007 | CA2613482A1 Methods and compositions for diagnosis and treatment of influenza |
| 02/15/2007 | CA2583274A1 Enhancement of b cell proliferation by il-15 |
| 02/14/2007 | EP1752539A2 cDNA for human methylenetetrahydrofolate reductase |
| 02/14/2007 | EP1752538A1 Human bikunin |
| 02/14/2007 | EP1752472A2 Chimeric amyloid beta peptides |
| 02/14/2007 | EP1752470A1 Gag binding proteins |
| 02/14/2007 | EP1752469A2 Long lasting fusion peptide inhibitors for HIV infection |
| 02/14/2007 | EP1752467A1 Inhibitors of cancer cell, t-cell and keratinocyte proliferation |
| 02/14/2007 | EP1752466A2 Process of purification of hcg and recombinant hcg purified by that method |
| 02/14/2007 | EP1752465A2 Linear VH-CH1-VH-CH1 heavy chain antibody fragment |
| 02/14/2007 | EP1752189A2 Microprojection array having a beneficial agent containing coating |
| 02/14/2007 | EP1752162A1 Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone |
| 02/14/2007 | EP1752161A2 Pulmonary surfactans comprising a polymyxin for improving the surface properties |
| 02/14/2007 | EP1752160A2 Epitope sequences |
| 02/14/2007 | EP1752159A1 Medicinal composition and therapeutic method |
| 02/14/2007 | EP1752158A1 Corneal neuritogenesis promoter containing pacap and its derivative |
| 02/14/2007 | EP1751554A1 Method for screening and compositions for treating cancers |
| 02/14/2007 | EP1751301A2 Endothelial cell apoptosis induced by fibrinogen gamma chain c-terminal fragment |
| 02/14/2007 | EP1751300A2 T-cell death-inducing epitopes |
| 02/14/2007 | EP1751271A2 Methods and compositions for the dietary management of autoimmune disorders |
| 02/14/2007 | EP1751192A1 Cross-linked antibodies |
| 02/14/2007 | EP1751189A1 Diagnostic and therapeutic applications of soluble lhcgr protein |
| 02/14/2007 | EP1751188A1 Splice variant of unc5h2 |
| 02/14/2007 | EP1751185A2 Tgf derepressors and uses related thereto |
| 02/14/2007 | EP1751184A2 Fgf-21 fusion proteins |
| 02/14/2007 | EP1751183A2 Fas associated factor 1 |
| 02/14/2007 | EP1751181A1 BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS |
| 02/14/2007 | EP1751179A2 Casein derived peptides and therapeutic uses thereof |
| 02/14/2007 | EP1751176A1 Cyclopeptide derivatives with anti-integrin activity |
| 02/14/2007 | EP1751175A1 Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| 02/14/2007 | EP1751094A2 Beta-peptides |
| 02/14/2007 | EP1750808A2 Myricitrin compounds for treating sleeping disorders |
| 02/14/2007 | EP1750773A1 Drugs for the prevention or treatment of immunodeficiencies, autoimmune diseases or for the induction of immune tolerance |
| 02/14/2007 | EP1750758A1 Use of factor viia for the treatment of burn traumas |
| 02/14/2007 | EP1750757A2 Methods of purifying chondroitinase and stable formulations thereof |
| 02/14/2007 | EP1750756A2 Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| 02/14/2007 | EP1750755A1 Methods and formulations for increasing intestinal function |
| 02/14/2007 | EP1750754A2 Human glp-1 mimetibodies, compositions, methods and uses |
| 02/14/2007 | EP1750753A1 A composition comprising pyy for the treatment of gastrointestinal disorders |
| 02/14/2007 | EP1750752A2 Compounds and methods for increasing neurogenesis |
| 02/14/2007 | EP1750751A1 Stabilized interferon liquid formulations |
| 02/14/2007 | EP1750750A1 Method of stabilizing proteins |
| 02/14/2007 | EP1750749A2 Il-28 and il-29 cysteine mutants for treating viral infection |
| 02/14/2007 | EP1750748A1 Use of the foamy virus bet protein for inactivating apobec |
| 02/14/2007 | EP1750747A1 Soluble lfa-3 polypeptide for treating viral disorders |
| 02/14/2007 | EP1750746A1 Methods of using il-1 antagonists to treat autoinflammatory disease |
| 02/14/2007 | EP1750745A1 Methods of inhibiting proinflammatory cytokine expression using ghrelin |
| 02/14/2007 | EP1750744A1 Medicament for the treatment of fungal infections, particularly aspergillosis |
| 02/14/2007 | EP1750743A2 Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases |
| 02/14/2007 | EP1750742A2 Methods of treating disease with random copolymers |
| 02/14/2007 | EP1750741A1 Methods of treating disease with random copolymers |
| 02/14/2007 | EP1750740A1 Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions |
| 02/14/2007 | EP1750739A1 Oxygenated dibenzo-alpha-pyrone chromoproteins |
| 02/14/2007 | EP1750738A1 Microbial biosurfactants as agents for controlling pests |
| 02/14/2007 | EP1750737A2 Improved method for identifying peptides in a biological sample |
| 02/14/2007 | EP1750734A2 Method of preparation and use of fibrinolytic enzymes in the treatment of disease |
| 02/14/2007 | EP1750733A1 METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII |
| 02/14/2007 | EP1750721A1 Topical cromolyn formulations |
| 02/14/2007 | EP1750711A2 Treatment of neurogenerative and inflammatory conditions with morphinan |
| 02/14/2007 | EP1750683A1 Sustained release formulations |
| 02/14/2007 | EP1750674A2 Microparticles for oral delivery |
| 02/14/2007 | EP1750672A2 Encapsulated transfer factor compositions and methods of use |
| 02/14/2007 | EP1750670A1 Buccal, polar and non-polar sprays containing propofol |
| 02/14/2007 | EP1750667A2 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 02/14/2007 | EP1750528A2 Alpha-msh-antagonist didpeptide conjugates |